Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

Abbott withdraws European MAA for Ozespa

Jan. 19, 2011

GSK develops novel lysophospholipid S1P1 receptor agonists

Jan. 18, 2011

Excaliard reports data from three phase II trials of EXC-001

Jan. 17, 2011

Vicept Therapeutics reports phase II data on V-101 in rosacea

Jan. 17, 2011

Self-assembling KGF-ELP nanoparticles show promise in wound healing

Jan. 17, 2011

ATX-101 enters European phase III trials for reduction of submental fat

Jan. 11, 2011

CardioVascular BioTherapeutics presents phase II data on CVBT-141B

Jan. 5, 2011

New target identified for treatment of psoriasis-associated skin inflammation

Jan. 5, 2011

BL-5010 is efficacious in nonsurgical removal of skin lesions in phase I/II trial

Jan. 3, 2011

Shionogi and AnGes to codevelop NFkB decoy oligo

Dec. 29, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...